eCysticFibrosis Review
No-cost CME from Johns Hopkins
Gratuit
4.2for iPhone, iPad and more
Age Rating
eCysticFibrosis Review Captures d'écran
About eCysticFibrosis Review
eCysticFibrosis Review is a no-cost CME program developed by Johns Hopkins University School of Medicine (JHUSOM) in partnership with DKBmed. Expert insight and analysis providing information directly relevant to cystic fibrosis care, through topic-focused newsletters summarizing the peer-reviewed literature with accompanying podcasts to illustrate how to apply that information in the clinic.
eCysticFibrosis Review is part of the highly successful eLiterature Review series. Over 50,000 health care providers are subscribed to eLiterature Review in areas such as viral hepatitis, primary care, pulmonology, HIV, multiple sclerosis, and diabetes. Join your colleagues in this highly-rated educational program.
eCysticFibrosis Review Volume 9 covers key topics such as:
-How to screen and have conversations with your patients about their mental health.
-What you should know about the recently approved triple combination modulator.
-Expert analysis of the current trial data for long-term CFTR therapy
It is practically impossible for time-pressed clinicians to stay current with new clinical developments by reading medical literature alone, despite the value of doing so. To address this, the Johns Hopkins University School of Medicine (JHUSOM), in partnership with DKBmed, has enhanced the way clinicians receive this vital information through our highly successful eLiterature Review series, spanning a variety of disease states and covering a wide range of clinical expertise. The nuances of each disease require a tailored approach to facilitate optimal learning techniques and knowledge retention. In previous eLiterature Review, some programs have been specifically directed to the specialist practitioner (eg, eOphthalmology, eNeonatalogy), but the majority have targeted a combination of both specialists and primary care clinicians that treat patients with chronic disease (eg, eDiabetes, eViralHepatitis).
What clinicians are saying about eCysticFibrosis Review:
“You guys saved my day!”
“I’m always having trouble keeping up with literature – this makes it so much easier!”
“I very much enjoyed the synopses of the studies with the questions after. They really helped me learn the material!”
eCysticFibrosis Review is part of the highly successful eLiterature Review series. Over 50,000 health care providers are subscribed to eLiterature Review in areas such as viral hepatitis, primary care, pulmonology, HIV, multiple sclerosis, and diabetes. Join your colleagues in this highly-rated educational program.
eCysticFibrosis Review Volume 9 covers key topics such as:
-How to screen and have conversations with your patients about their mental health.
-What you should know about the recently approved triple combination modulator.
-Expert analysis of the current trial data for long-term CFTR therapy
It is practically impossible for time-pressed clinicians to stay current with new clinical developments by reading medical literature alone, despite the value of doing so. To address this, the Johns Hopkins University School of Medicine (JHUSOM), in partnership with DKBmed, has enhanced the way clinicians receive this vital information through our highly successful eLiterature Review series, spanning a variety of disease states and covering a wide range of clinical expertise. The nuances of each disease require a tailored approach to facilitate optimal learning techniques and knowledge retention. In previous eLiterature Review, some programs have been specifically directed to the specialist practitioner (eg, eOphthalmology, eNeonatalogy), but the majority have targeted a combination of both specialists and primary care clinicians that treat patients with chronic disease (eg, eDiabetes, eViralHepatitis).
What clinicians are saying about eCysticFibrosis Review:
“You guys saved my day!”
“I’m always having trouble keeping up with literature – this makes it so much easier!”
“I very much enjoyed the synopses of the studies with the questions after. They really helped me learn the material!”
Show More
Quoi de neuf dans la dernière version 4.2
Last updated on May 13, 2020
Vieilles Versions
A new volume of eCysticFibrosis Review just launched! This new volume will continues our focus on helping you improve the health and quality of life of your patients through best-practice treatment. Volume 9 covers:
-Mental health: how to recognize and address mental health issues in patients with CF and their care team
-CFTR Modulators: updates on the recently approved triple combination modulator therapy.
-Expert analysis of the current trial data for long-term CFTR therapy.
-Antibiotic treatment: how do multidrug resistance and CFTR therapy affect antibiotic treatment.
-Bug fixes
-Mental health: how to recognize and address mental health issues in patients with CF and their care team
-CFTR Modulators: updates on the recently approved triple combination modulator therapy.
-Expert analysis of the current trial data for long-term CFTR therapy.
-Antibiotic treatment: how do multidrug resistance and CFTR therapy affect antibiotic treatment.
-Bug fixes
Show More
Version History
4.2
May 13, 2020
A new volume of eCysticFibrosis Review just launched! This new volume will continues our focus on helping you improve the health and quality of life of your patients through best-practice treatment. Volume 9 covers:
-Mental health: how to recognize and address mental health issues in patients with CF and their care team
-CFTR Modulators: updates on the recently approved triple combination modulator therapy.
-Expert analysis of the current trial data for long-term CFTR therapy.
-Antibiotic treatment: how do multidrug resistance and CFTR therapy affect antibiotic treatment.
-Bug fixes
-Mental health: how to recognize and address mental health issues in patients with CF and their care team
-CFTR Modulators: updates on the recently approved triple combination modulator therapy.
-Expert analysis of the current trial data for long-term CFTR therapy.
-Antibiotic treatment: how do multidrug resistance and CFTR therapy affect antibiotic treatment.
-Bug fixes
4.1
Mar 28, 2020
few bugs fixed
4.0
Feb 13, 2020
-Performance enhancements
-Design and user interface improvements
-Bug fixes
-Design and user interface improvements
-Bug fixes
3.3
Aug 16, 2017
Updated copy
3.2
Feb 6, 2017
Updated copy
3.1
Jan 29, 2017
Updated user experience.
3.0.1
Jul 12, 2016
updated icons.
3.0.0
Feb 1, 2016
New user interface
2.3.0
Mar 4, 2015
New user interface and other features.
1.0.0
Oct 14, 2013
eCysticFibrosis Review FAQ
Cliquez ici pour savoir comment télécharger eCysticFibrosis Review dans un pays ou une région restreints.
Consultez la liste suivante pour voir les exigences minimales de eCysticFibrosis Review.
iPhone
Nécessite iOS 10.0 ou version ultérieure.
iPad
Nécessite iPadOS 10.0 ou version ultérieure.
iPod touch
Nécessite iOS 10.0 ou version ultérieure.
eCysticFibrosis Review prend en charge Anglais